Arbutus Biopharma Corp
ABUS - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$834.03M
Close$
$-2.80
169.9% downside
Current Fair Value
169.9% downsideOvervalued by 169.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $834.03 Million |
|---|---|
| Enterprise Value | $815.37 Million |
| Earnings per Share | $-0.17 |
| Beta | 0.62 |
| Outstanding Shares | 197,470,724 |
Return
| Return on Equity | 59.16% |
|---|---|
| Return on Assets | 55.85% |
| Return on Invested Capital | 54.56% |
Valuation & Multiples
| P/E Ratio | 5.33 |
|---|---|
| PEG | -1.75 |
| Price to Sales | - |
| Price to Book Ratio | 4.0 |
| Enterprise Value to Revenue | 4.49 |
| Enterprise Value to EBIT | 5.52 |
| Enterprise Value to Net Income | 5 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.02
Consensus analyst estimateRevenue Estimate
$700,000
Consensus analyst estimateNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.02
Consensus analyst estimateRevenue Estimate
$1.00 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 95.02% |
|---|---|
| Total Calls | 250,000▲ 33.98% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.24%▼ 71.69% |
|---|---|
| Total Invested | $2.30M▼ 99.66% |
| Investors Holding | 16▼ 166.00% |
About Arbutus Biopharma Corp
CEO: William Collier
